Bharat Biotech

Bharat Biotech's Covaxin Get DCGI Nod For Emergency Use For Children Aged Above 12 Yrs

Bharat Biotech Seeks Nod For Phase 3 Trial Of Intra-Nasal Covid Vaccine As Booster Dose

​Covaxin Was 50% Effective Against Symptomatic Covid During Second Wave: Real-​World Study In AIIMS

Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet

Negativity ‘Hurt Us’: Bharat Biotech Chairman Dr Krishna Ella On Delay In WHO Nod To Covaxin

Bharat Biotech's US Partner Ocugen Seeks Approval On Covaxin's Use For Children Below 18 Years

WHO Approves Bharat Biotech's Covaxin For Emergency Use Listing

Bharat Biotech's Covaxin Recognised By Australia. Country Open Borders For International Travel

'Bharat Biotech Submitting Data Regularly': WHO On Covaxin Getting EUL Nod

Covaxin Clinical Trials: Bharat Biotech’s US Partner Ocugen Files Request With FDA

WHO Seeks 'Additional Clarifications' From Covaxin Before Giving Nod To Emergency Use Listing

Covaxin WHO Approval: Technical Advisory Group To Consider EUL In Meeting On Oct 26